Status:
COMPLETED
Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This present study is specifically designed to examine the efficacy and safety of a high pre-treatment dose of atorvastatin in Asian patients with NSTE-ACS in China and the Republic of Korea, by using...
Eligibility Criteria
Inclusion
- Non-ST elevated ACS; LDL-C \> 80 mg/dl
Exclusion
- ST elevated acute myocardial infarction; previously or currently treated with atorvastatin or other statins
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
499 Patients enrolled
Trial Details
Trial ID
NCT00728988
Start Date
September 1 2008
End Date
April 1 2010
Last Update
February 21 2021
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Guangzhou, Guangdong, China, 510100
2
Pfizer Investigational Site
Changsha, Hunan, China, 410008
3
Pfizer Investigational Site
Shenyang, Liaoning, China, 110004
4
Pfizer Investigational Site
Shenyang, Liaoning, China, 110016